Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF（2）
April 21, 2008
- Orchid of India Announces Entry into Japanese Market
April 21, 2008
- NEW PRODUCTS
April 21, 2008
- Generic Makers to Embark on Mergers, Tie-ups: Mr Sawai
April 21, 2008
- NCC to Take Full Advantage of New System to Provide Advanced Healthcare to More Patients
April 21, 2008
- Doctors Should Collect Information Themselves when Using Generics: Prof. Ogata
April 21, 2008
- Further Spread of Hepatitis C Viral Infections Unlikely: Chugai Seminar
April 21, 2008
- Korosho to Punish Healthcare Providers Who Don't Try to Use More Generics: Mr Nakagaki
April 21, 2008
- Drug Cost Cut by 6% by Generic Substitution in 1st Week of April: Nihon Chouzai
April 21, 2008
- New Prescription Form Is Working Well: Mr Takeda
April 21, 2008
- No More Than 10% of Prescriptions Will Be Substituted with Generics: Dr Muto
April 21, 2008
- PMDA Should Support R&D from Patients' Viewpoints: New PMDA Chief Executive
April 21, 2008
- Opinions Split on Whether Only Pharmacists Should Be Allowed to Manage Stores
April 21, 2008
- TOPICS／Q&A Issued on GL on Drugs Using Autologous Cells
April 21, 2008
- OPINION／How to Get Lucky in Your Pharma Career
April 21, 2008
- LDP Begins Discussions on the Need for a Japanese Version of FDA
April 21, 2008
- LDP Proposes Creation of a Japanese Version of FDA
April 21, 2008
- Chugai Reinforces European Sales Structure
April 14, 2008
- Kirin Pharma, Kyowa Hakko Announce Restructuring of R&D Systems
April 14, 2008
- Mochida to Undertake Challenges in New Fields
April 14, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…